MedTech Dive

6 days ago | medtechdive.com | Elise Reuter

By the numbersQ1 revenue: $569 million29% increase year over yearNet income: $35.4 million31% decrease year over yearNew Insulet CEO Ashley McEvoy set out her priorities for the diabetes technology company on Thursday. “Insulet is already a standout success story,” McEvoy told investors during her first call after taking on the role, adding that the firm is one of the fastest-growing businesses in medtech.

6 days ago | medtechdive.com | Susan Kelly

This audio is auto-generated. Please let us know if you have feedback. The Securities and Exchange Commission has concluded its investigation into Illumina’s 2021 acquisition of liquid biopsy maker Grail and recommended no enforcement action be taken, the company said Thursday. Illumina spun off Grail in 2024, following several tumultuous years in which regulators had challenged the $8 billion takeover, ultimately forcing the separation.

6 days ago | medtechdive.com | Susan Kelly

This audio is auto-generated. Please let us know if you have feedback. Jeremy Walsh will lead the Food and Drug Administration’s artificial intelligence efforts as chief AI officer, the agency confirmed Thursday. The appointment comes as the FDA launches the rollout of a generative AI platform across its centers, according to the statement.

6 days ago | medtechdive.com | Elise Reuter

A growing number of diabetes technology companies are advocating for greater access to medical devices for people with Type 2 diabetes. In the last year, the Food and Drug Administration has granted the first expanded indications for automated insulin delivery systems in people with Type 2 diabetes. The systems combine pumps and glucose monitors to automatically adjust insulin delivery based on blood glucose levels.

6 days ago | medtechdive.com | Nick Paul Taylor

Bausch + Lomb has received a CE mark for its Luxlife intraocular lens, the company said Wednesday. The CE mark positions Bausch + Lomb to make the lens, which supports near, intermediate and far vision, in Europe in the coming weeks. Bausch + Lomb’s range of Lux lenses is based on a different platform than its Envista IOLs. Some Envista lenses were recently recalled in the U.S. but weeks later after the company identified a raw material from a vendor as the cause of inflammatory reactions.